louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01134211: Clinical Comparison of Two Daily Disposable Lenses Among Daily Disposable Lens Wearers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Myopia
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2010-05-31
Enrollment: 316
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The primary objective of this trial is to evaluate the subjective performance of two different daily disposable contact lenses in a population of daily disposable lens wearers.


Eligibility criteria: Inclusion Criteria:

* Currently wearing any spherical daily disposable lens in daily wear, daily disposable modality for at least 3 months prior to enrollment with the exception of the 2 study products
* Currently Wearing lenses at least 8 hrs/day and 5 days/week.
* Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

* Eye injury or surgery within twelve weeks immediately prior to enrollment for this trial.
* Pre-existing ocular irritation that would preclude contact lens fitting.
* Currently enrolled in any clinical trial.
* Evidence of systemic or ocular abnormality, infection, or disease which is likely to affect successful wear of contact lenses or use of their accessory solutions as determined by the investigator.
* Any use of medications for which contact lens wear could be contraindicated as determined by the investigator.
* Prior history of corneal or refractive surgery.
* Requires monovision correction.
* Other protocol-defined exclusion criteria may apply.

Primary outcomes:
measure: subjective ratings and preferences
timeFrame: 2 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Heikendorf
country: Germany
facility: W.Hartwig - Qualität in jeder Hinsicht
Study officials:
References:
citation: OVS, Marx et al. Subjective Performance of hydrogel and silicone hydrogel daily disposable contact lenses). AAO poster presentation 2014.
Clinical trial NCT04780711: Prevalance of Temporomandibular Joint Disease
Official title: Prevalance of Temporomandibular Joint Disease in Medical School Students
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Temporomandibular Joint Disorders
Keywords: Temporomandibular Joint Disorders
Lead sponsor: Abant Izzet Baysal University
Sponsor class: OTHER
First posted: 2021-03-03
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: We planned to include 500 volunteer students between the ages of 18-35, studying at Bolu Abant Izzet Baysal University Faculty of Medicine, with or without TMJ symptoms and agreeing to participate in the study.

Brief summary: Temporomandibular joint (TMJ) disorders are common problems in the society and involve the masticator muscles, jaw joint and related structures. Since TMJ disorders affect functions such as eating and speaking, they can cause important problems in the daily life of the patient. Therefore, its diagnosis and treatment are of great importance. In the treatment of these patients, methods such as analgesic and anti-inflammatory drugs, splint, exercise, physical therapy modalities can be applied.

Detailed description: Although the prevalence of TMJ disease detected in the community is between 40-60%, the rate of symptoms or clinical findings was reported to be 87% in a study including 1040 people. Incomplete clarification of the etiology and pathogenesis, the lack of standard diagnostic and treatment approaches cause patients to learn to live with this problem, and severe pain and limitation of movement cause a decrease in quality of life and loss of workforce. Specific pathologies such as systemic inflammatory diseases, tumor, fracture, developmental anomaly cause temporomandibular joint diseases. It also causes a wider group of non-specific TMB originating from the musculoskeletal system.When the literature was reviewed, no publications on the frequency of TMJ joint disease were found in medical faculty students.

Eligibility criteria: Inclusion Criteria:

* Being a medical student
* Being between the ages of 18-35

Exclusion Criteria:

* Students who do not want to participate in the study

Primary outcomes:
measure: Mouth opening
timeFrame: Baseline
measure: Tenderness in the masseter and temporal muscles on deep palpation
timeFrame: Baseline
measure: Click in the temporomandibular joint
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Bolu
country: Turkey
facility: Elif Yakşi
Study officials:
affiliation: Abant İzzet Baysal University Medical Faculty
name: Elif Yakşi, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05010811: Two Cases of Pulmonary Cysticercosis Manifesting as Pleural Effusion: Case Report and Literature Review
Official title: Two Cases of Pulmonary Cysticercosis Manifesting as Pleural Effusion: Case Report and Literature Review
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cysticercosis
Keywords: Cysticercosis
pleural effusion
pulmonary
Lead sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Sponsor class: OTHER
First posted: 2021-08-18
Enrollment: 2
Sex: ALL
Minimum age (years): 45
Maximum age (years): 67
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Two patients with pleural effusion presenting with chest tightness and chest pain were enrolled in this study with a definitive diagnosis of cysticercosis confirmed by pleural effusion examination

Brief summary: Isolation lung cysticercosis reports are rare in literature. Most lung lesions were characterized by nodules. The investigators access one case which was characterized with pulmonary cavity and pleural effusion by Gupta N, et al in 2015 from PUBMED and Medline. But pleural effusion and exudative lesions is reported for the first time.

Detailed description: Cysticercosis is an important public health problem in developing countries. The major involvement sites are the central nervous system and the eyes，although striated muscles and subcutaneous tissues are frequently involved in the disseminated form of disease. Pulmonary involvement in cysticercosis is very rare and ill-defined nodular shadows distributed throughout the lung is the usual radiological presentation. Only one case of cysticercosis presenting as lung cavity with pleural effusion has been reported so far in literature. The investigators describe two cases in which pleural effusion due to cysticercosis were detected on X and CT.

Eligibility criteria: Inclusion Criteria:

1. Clinical diagnosis of Pulmonary Cysticercosis。
2. With pleural effusion

Exclusion Criteria:

1.No cysticercosis was found by biopsy or antibody test

Primary outcomes:
measure: Amount of pleural effusion
timeFrame: 9 months
measure: Rate of Eosinophil ratio
timeFrame: 9 months
measure: Changes of lesions under chest radiography or CT
timeFrame: 9 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: the same research center
name: Pingli Wang, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT03758911: Perspectives on Bone Marrow Donors Who Donate for Their Parent
Official title: Perspectives on the Adolescent, Young Adult, and Adult Experience as Donors for Their Parent Undergoing Haploidentical Bone Marrow Transplants
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Bone Marrow Transplant
Keywords: bone marrow
stem cell
donor
interview
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sponsor class: OTHER
Collaborators: name: Duke University
First posted: 2018-11-29
Enrollment: 16
Sex: ALL
Minimum age (years): 13
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Participants included adolescents, young adults, or adults who had donated bone marrow or peripheral blood stem cells for their parent in the past 1 - 6 months.

Brief summary: The purpose of this pilot study is to explore the role of family function on decision-making for bone marrow donors who donated for their parent, and to assess the unique supportive care needs of these participants. Semi-structured interviews were conducted with participants to identify overarching themes of the donation experience.


Eligibility criteria: Inclusion Criteria:

* Donated bone marrow or peripheral blood stem cells for their parent in the past 1-6 months
* Willing to participate in mandatory audio recorded telephone interview
* Able to participate in interview without assistance
* Must be English speaking
* Transplant recipient (parent) must be living

Exclusion Criteria:

* Unable to provide oral consent for participation (for minors- unable to obtain parental consent and/or oral assent from child for participation)

Primary outcomes:
measure: Themes influencing donors' decision-making as assessed by words used during interview responses
timeFrame: Day 1
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Johns Hopkins University
name: Nina D Wagner-Johnston, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00550511: Randomized Study Evaluating the Role of Surgeon-Performed Ultrasound in the Management of the Acute Abdomen
Official title: Randomized Study Evaluating the Role of Surgeon-Performed Ultrasound in the Management of the Acute Abdomen
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Abdominal Pain
Keywords: Abdominal pain
ultrasound
surgery
emergency department
diagnostic accuracy
Lead sponsor: Karolinska Institutet
Sponsor class: OTHER
Collaborators: name: Region Stockholm
First posted: 2007-10-30
Enrollment: 800
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to evaluate whether surgeon-performed ultrasound as a supplement to clinical investigation when a patient presents with abdominal pain in the emergency department can improve the management of the patient.

Detailed description: Surgeon-performed ultrasound bedside in the emergency department when a patient presents with abdominal pain is quite common in Continental Europe and USA. It is considered to be implemented at emergency departments all over Sweden. This is the first randomized study performed to evaluate the method. In our study we compare diagnostic accuracy and further management of patients admitted to the emergency department for abdominal pain, with or without examination with surgeon-performed ultrasound bedside.

Eligibility criteria: Inclusion Criteria:

* Admitted to emergency ward for abdominal pain
* 18 years or older

Exclusion Criteria:

* Pregnancy
* Condition that has to be taken care of immediately
* Inability to communicate with the investigator
* Previously diagnosed abdominal condition
* Severe drug or alcohol addiction
* Dementia

Primary outcomes:
measure: Proportion of correct diagnosis
timeFrame: 6 weeks
Secondary outcomes:
measure: Time consumption in emergency department Time to decision about surgical intervention Amount of complementary examinations Amount of hospital admissions Patient satisfaction in the emergency ward and at follow up Consumption of health care
timeFrame: 2 years
Other outcomes:
Locations:
Study officials:
affiliation: Karolinska Institutet, Department of Medicine, Clinical epidemiology unit
name: Johanna Adami, ass prof
role: PRINCIPAL_INVESTIGATOR
affiliation: Karolinska Institutet, Department of Surgery, Stockholm South General Hospital
name: Anna Lindelius, MD
role: STUDY_DIRECTOR
References:
citation: Lindelius A, Torngren S, Nilsson L, Pettersson H, Adami J. Randomized clinical trial of bedside ultrasound among patients with abdominal pain in the emergency department: impact on patient satisfaction and health care consumption. Scand J Trauma Resusc Emerg Med. 2009 Nov 27;17:60. doi: 10.1186/1757-7241-17-60.
citation: Lindelius A, Torngren S, Pettersson H, Adami J. Role of surgeon-performed ultrasound on further management of patients with acute abdominal pain: a randomised controlled clinical trial. Emerg Med J. 2009 Aug;26(8):561-6. doi: 10.1136/emj.2008.062067.
Clinical trial NCT04158011: A Retrospective Study of Patients With Leukemia Relapse in the CNS Treated With CAR T Cells
Official title: CARs for CNS-Leukemia Relapse: A Retrospective International Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Acute Lymphoblastic Leukemia
Keywords: CAR T cells
CNS leukemia
Lead sponsor: Sheba Medical Center
Sponsor class: OTHER_GOV
First posted: 2019-11-08
Enrollment: 80
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Retrospective review of patients with CNS - involvement of B-cell ALL, treated with CAR T cells targeting CD19 of either an institutional-based clinical trial, a pharma-based clinical trial or commercial product.

Brief summary: CAR T cells targeting CD19 have been approved for patients with relapsed or refractory ALL, failing two or more prior protocols. Several institutional-based studies with other CAR T cells targeting CD19 have demonstrated outstanding response rates in patients with refractory disease, and the ability of CAR T cells to clear CNS leukemia. Nevertheless, these cases are sparse and have never been reported collectively.

Here, we aim to retrospectively assess toxicity and long term outcome of patients treated with CAR T cells for CNS relapse of ALL.


Eligibility criteria: Inclusion Criteria:

* Prior diagnosis of B-cell acute lymphoblastic leukemia involving the central nervous system
* Treatment with CAR T cells (either on a clinical trial or commercial use) due to this indication

Primary outcomes:
measure: Overall survival
timeFrame: 6 months
Secondary outcomes:
measure: Incidence of CAR-related CRS or ICANS per ASCTC guidelines
timeFrame: 2 months
measure: Leukemia-free survival
timeFrame: 6 months
measure: CNS-leukemia free survival
timeFrame: 6 months
Other outcomes:
Locations:
city: Ramat Gan
country: Israel
facility: Chaim Sheba Medical Center
Study officials:
References:
Clinical trial NCT00195611: Study of Streptococcus Pneumoniae in Nose and Throats of Infants With Acute Otitis Media
Official title: Observational Study of the Rhinopharyngeal Carriage of Streptococcus Pneumoniae (Sp) in Infants With Acute Otitis Media (AOM)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Otitis Media
Otitis Media With Effusion
Pneumococcal Infections
Keywords: Middle Ear Infection
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Sponsor class: INDUSTRY
First posted: 2005-09-19
Enrollment: 3293
Sex: ALL
Minimum age (years): 6
Maximum age (years): 24
Standard ages: CHILD
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Screening, Cross-Sectional, Defined Population, Prospective Study

Brief summary: The aim of this study is to assess in France the impact of Prevenar on the possible evolution of the pneumococcal serotypes distribution and antibiotic resistance in NP samples of children with AOM.


Eligibility criteria: Inclusion Criteria:

* Infants aged from 6 to 24 months
* Presenting with AOM (ear infection)
* Patients must not have received any antibiotic therapy within the past 7 days.

Other inclusion applies.

Exclusion Criteria:

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Auch
country: France
city: Brest
country: France
city: Canne La Boca
country: France
city: Chalons En Champagne
country: France
city: Chambery
country: France
city: Combs La Ville
country: France
city: Creteil
country: France
city: Draguignan
country: France
city: Essey Les Nancy
country: France
city: Fontenay Sous Bois
country: France
city: Grenoble
country: France
city: Grigny
country: France
city: Lagny
country: France
city: Les Lilas
country: France
city: Les Ulis
country: France
city: Lyon
country: France
city: Marquette
country: France
city: Marseille
country: France
city: Massy
country: France
city: Molsheim
country: France
city: Paris
country: France
city: Paris
country: France
city: Paris
country: France
city: Paris
country: France
city: Paris
country: France
city: Rouen
country: France
city: Saint Brieuc
country: France
city: Saint Maur Des Fosses
country: France
city: Selestat
country: France
city: Thionville
country: France
city: Toulouse
country: France
city: Tours
country: France
city: Vandoeuvre Les Nancy
country: France
city: Vence
country: France
city: Villeneuve Les Avignon
country: France
Study officials:
affiliation: Wyeth is now a wholly owned subsidiary of Pfizer
name: Medical Monitor
role: STUDY_DIRECTOR
References:
Clinical trial NCT03060811: Mediterranean Diet, Trimethylamine N-oxide (TMAO) and Anti-oxidants in Healthy Adults
Official title: Mediterranean Diet, Trimethylamine N-oxide (TMAO) and Anti-oxidants in Healthy Adults
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Mediterranean Diet
Trimethylamine N-oxide
Cardiovascular Risk Factor
Lead sponsor: Federico II University
Sponsor class: OTHER
First posted: 2017-02-23
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy subjects (n=84) aged 21-50 years with a BMI of 20-29.9 kg/m2, chosen among hospital volunteers and employees from the same geographical area. A sample size of n=40 was determined from a power analysis of a within-subject design to detect a 10% difference of plasma TMAO concentration at alfa\<0.05 and β =0.8. Participants were screened by the use of a blood chemistry profile, cell count, and health history questionnaire.

Brief summary: Trimethylamine N-oxide (TMAO) is a small organic compound naturally present in fish and seefood or generated by the bacterial breakdown of dietary phosphatidylcholine and carnitine-containing foods within the human gut microbiome. Elevated serum TMAO was previously reported to be associated with an elevated risk for cardiovascular events.

Aim of this study was to investigate the association between plasma levels of TMAO with the Mediterranean diet in a cohort of healthy adults.


Eligibility criteria: Inclusion Criteria:

healthy subjects of both gender

Exclusion Criteria:

* age\>65 years
* \> BMI 30 kg/m2
* vegetarians
* smokers
* gastrointestinal diseases or complaints
* chronic illnesses or other metabolic diseases (including trimethylaminuria)
* abnormal blood chemistry values indicative of organ dysfunctions
* nutritional supplements, antibiotics or probiotics within 2 months of recruitment

Primary outcomes:
measure: Adherence to Mediterranean Diet by Predimed Questionnaire
timeFrame: September 2016 to December 2016
measure: Trimethylamine N-oxide plasma levels
timeFrame: September 2016 to December 2016
Secondary outcomes:
measure: cardiovascular risk
timeFrame: September 2016 to December 2016
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01012011: Regulatory Post Marketing Surveillance Study on Nexavar®
Official title: Regulatory Post Marketing Surveillance Study on Nexavar®
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Carcinoma, Hepatocellular
Carcinoma, Renal Cell
Keywords: Carcinoma, Hepatocellular
Carcinoma, Renal Cell
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2009-11-11
Enrollment: 2845
Sex: ALL
Minimum age (years): 20
Maximum age (years): 91
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with diagnosis of advanced renal cell carcinoma or hepatocellular carcinoma and decision taken by the physician to precribe Nexavar

Brief summary: This surveillance are to identify problems/questions regarding adverse events, factors that are considered to affect on safety and efficacy in the clinical practice of using Nexavar

Detailed description: The objectives of this surveillance are to identify problems/questions regarding the followings in the clinical practice of using Nexavar®.

1. Unknown adverse events (in particular, serious adverse events)
2. Identification of adverse events occurred in the real practice.
3. Factors that are considered to affect on safety.
4. Factors that are considered to affect on effectiveness

Eligibility criteria: Inclusion Criteria:

* Patients with diagnosis of advanced RCC or HCC and decision taken by the physician to prescribe Nexavar.

Exclusion Criteria:

* Exclusion criteria must be read in conjunction with the local product information but patients who are participating in other interventional studies currently will be excluded.

Primary outcomes:
measure: Adverse events collection
timeFrame: From start of treatment to 4 weeks after discontinuation of treatment
Secondary outcomes:
measure: Duration of treatment, dosage and indication
timeFrame: Whole treatment period
measure: Tumor status
timeFrame: Whole treatment period
measure: Performance status
timeFrame: Whole treatment period
Other outcomes:
Locations:
city: Many Locations
country: Korea, Republic of
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References: